Allergy Therapeutics

Research Allergy Therapeutics (AGY) on Bullrun: market cap GBX 45.97B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAGY
• ExchangeLSE
• CountryUnited Kingdom
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyGBX
• Market capGBX 45.97B
• Financial periodFY2025
• RevenueGBP 55.04M
• Revenue growth-0.3%
• Net income-GBP 40.13M
• Free cash flow-GBP 31.53M
• Gross margin53.2%

Valuation Snapshot

latest market cap is GBX 45.97B.

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products.

Frequently asked questions

What is Allergy Therapeutics's market cap?

Allergy Therapeutics's market capitalization is GBX 45.97B.

What does Allergy Therapeutics do?

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally.